Search
Services
Services
When to Come
Locations
Menu
Give
Volunteer
Contact
Menu
Return to OU Health
Insurance & Billing
Patient Portal
Education
Health Professionals
Ways to Give
Return to OU Health
Ways To Give
Ways To Give
Ways To Give
Ways To Give
Ways To Give
To Our Family of Philanthropies
To Our Family of Philanthropies
Find A Location
ER vs Urgent Care
When to Come
About Us
FAQ
Newsroom & Media
Fundraise
Make a Gift
Make a Gift
405-494-8600
Clinical Trials
Search Clinical Trials
Search Trials
Disease Site
Select
Anus
Bones and Joints
Brain and Nervous System
Breast
Cervix
Colon
Corpus Uteri
Esophagus
Eye and Orbit
Hodgkin Lymphoma
Ill-Defined Sites
Kaposi's Sarcoma
Kidney
Larynx
Leukemia, other
Lip, Oral Cavity and Pharynx
Liver
Lung
Lymphoid Leukemia
Melanoma, Skin
Multiple Myeloma
Multiple Sites
Mycosis Fungoides
Myeloid and Monocytic Leukemia
Non-Hodgkin Lymphoma
Other
Other Digestive Organ
Other Endocrine System
Other Female Genital
Other Hematopoietic
Other Male Genital
Other Respiratory and Intrathoracic Organs
Other Skin
Other Urinary
Ovary
Pancreas
Prostate
Rectum
Small Intestine
Soft Tissue
Stomach
Thyroid
Unknown Sites
Urinary Bladder
Clear Filters
All Clinical Trials
A Phase II Study Evaluating the effect of GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) on Second Look Laparoscopy (SLL) when Administered in Combination with Bevacizumab (BEV) and Neoadjuvant Chemotherapy (NACT) in Subjects Newly Diagnosed with Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Protocol Number: 201-21-202
Status: Open
View Details
Pre-Screening for Sensitivity to Investigational Anti-Cancer Drugs in Patients with Advanced Ovarian Cancer
Protocol Number: 2X-1000
Status: Open
View Details
Phase 2, Randomized, Prospective, Open Label, Parallel-Arm, Dose Optimization Study to Investigate the Safety, Tolerability, PK/PD, and Anti-Tumor Effect of 2X- 121 in Patients with Recurrent, Advanced Ovarian Cancer
Protocol Number: 2X-1002
Status: Open
View Details
OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy
Protocol Number: A012103
Status: Open
View Details
LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-risk Early-Stage Breast Cancer
Protocol Number: A012301
Status: Open (affiliates only)
View Details
ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients With Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy With HER2 Blockade
Protocol Number: A012303
Status: Open
View Details
Randomized Phase III Trial of MFOLFIRINOX +/- NIVOLUMAB VS. FOLFOX +/- NIVOLUMAB for First - Line Treatment of Metastatic HER2-NEGATIVE Gastroesophageal Adenocarcinoma
Protocol Number: A022102
Status: Open
View Details
Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors
Protocol Number: A031702
Status: Open
View Details
PREcision DIagnostics in Prostate Cancer Treatment (PREDICT)
Protocol Number: A032102
Status: Open
View Details
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Protocol Number: A032103
Status: Open
View Details
Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma -STRIKE
Protocol Number: A032201
Status: Open
View Details
GAIN-BCG: Gemcitabine Alternating with Intravesical BCG Randomized Against BCG Alone for Patients with Recurrent High Grade Non-Muscle Invasive Bladder Cancer
Protocol Number: A032303
Status: Open
View Details
Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma
Protocol Number: A051901
Status: Open
View Details
A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma
Protocol Number: A052101
Status: Open
View Details
Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecaptagene Vicleucel CAR-T in Multiple Myeloma Patients
Protocol Number: A062102
Status: Open
View Details
